Pharmabiz

Quotient Sciences extends commercial manufacturing partnership with Ipsen for an ultra-rare disease treatment

Quotient Sciences extends commercial manufacturing partnership with Ipsen for an ultra-rare disease treatment: Philadelphia, Pennsylvania Saturday, February 28, 2026, 10:00 Hrs [I ...
Pharmabiz

Eli Lilly's oral GLP-1, orforglipron outperforms blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial

Our Bureau, Mumbai Saturday, February 28, 2026, 09:00 Hrs [IST] ...
Pharmabiz

CDSCO introduces SHRESTH index to improve performance of state drug regulatory authorities

CDSCO introduces SHRESTH index to improve performance of state drug regulatory authorities: Shardul Nautiyal, Mumbai Saturday ...
Pharmabiz

India’s neurodevelopment care sees decisive shift toward structured, evidence-based informed pathways: Nitin Bindlish

India’s neurodevelopment care sees decisive shift toward structured, evidence-based informed pathways: Nitin Bindlish: Nandita Vijayasimha, Bengaluru Saturday, February 28, 2026 ...
Pharmabiz

TN, Karnataka, Rajasthan declare highest number of NSQs in January

TN, Karnataka, Rajasthan declare highest number of NSQs in January: Gireesh Babu, New Delhi Saturday, February 28, 2026, 08:00 Hrs [IST] Around 29% of the total Not of Standard Qu ...
Pharmabiz

DoP amends NIPERs Council Rules to enable chairperson to take action in emergency situations

DoP amends NIPERs Council Rules to enable chairperson to take action in emergency situations: Gireesh Babu, New Delhi Saturday, February 28, 2026, 08:00 Hrs [IST] The Department o ...
Pharmabiz

IDEAYA Biosciences begins patient enrolment in phase 1 trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC

IDEAYA Biosciences begins patient enrolment in phase 1 trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC: South San Francisco, California Friday, February 27, 2026 ...
Pharmabiz

US FDA accepts Vanda Pharmaceuticals’ BLA for imsidolimab to treat Generalized Pustular Psoriasis

US FDA accepts Vanda Pharmaceuticals’ BLA for imsidolimab to treat Generalized Pustular Psoriasis: Washington Friday, February 27, 2026, 17:00 Hrs [IST] Vanda Pharmaceuticals In ...
Pharmabiz

Mevion Medical Systems’ MEVION S250-FIT Proton Therapy System receives European Union CE marking

Mevion Medical Systems’ MEVION S250-FIT Proton Therapy System receives European Union CE marking: Littleton, Massachusetts Friday, February 27, 2026, 16:00 Hrs [IST] Mevion Medi ...
Pharmabiz

Melodia Therapeutics receives US patent covering MLD-151

Melodia Therapeutics AG, a clinical-stage biotechnology company based in Basel, Switzerland, announced that the United States Patent and Trademark Office (USPTO) has granted a key US patent covering a ...
Pharmabiz

START appoints Dr Frank Smith as president of its XenoSTART preclinical research business unit

START appoints Dr Frank Smith as president of its XenoSTART preclinical research business unit: San Antonio, Texas Friday, February 27, 2026, 14:30 Hrs [IST] The START Center for ...
Pharmabiz

China NMPA accepts for priority review GSK’s NDA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis

China NMPA accepts for priority review GSK’s NDA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Friday, February 27, 2026, 14: ...